Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 149

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 149
---
 of
negotiations; due diligence considerations (including with respect to a potential site visit in China); and the proposed timing of the transaction. Aadi’s management team also presented regarding the proposed
non-binding term sheet, including the request by WuXi Biologics for mutual exclusivity, such that Aadi would exclusively negotiate with WuXi Biologics with respect to the
in-licensing of new assets. Aadi’s board of directors discussed the foregoing matters with the management team and related items, including, among other things, the estimated cash required to develop the in-licensed assets, anticipated timing for IND filings for product candidates developed from the in-licensed assets, and related financing considerations. Following
discussion, Aadi’s board of directors authorized Aadi to enter into the proposed non-binding term sheet on the terms presented.

On August 21, 2024, Dr. Lennon signed on behalf of Aadi and delivered to WuXi Biologics a final term sheet (the “Term Sheet”) which
reflected the terms set forth in the August 18 Term Sheet. On August 27, 2024, representatives of WuXi Biologics countersigned the Term Sheet and delivered it to representatives of Aadi.

On August 22, 2024, representatives of Aadi, Wilson Sonsini and WuXi Biologics met via videoconference to discuss intellectual property due diligence
related to the ADC Programs.

On August 22, August 29 and September 12, 2024, the Aadi management team presented to the Strategic
Transaction Committee regarding Aadi’s ongoing confirmatory due diligence of the ADC Programs and related items, including, among other things, anticipated development timelines and resource and budget needs.

On September 5 and September 11, 2024, representatives of Aadi, WuXi Biologics, Hangzhou DAC and their respective legal counsel met via
videoconference to discuss intellectual property due diligence related to the ADC Programs, including the CPT113 linker-payload system developed by Hangzhou DAC.

On September 9, 2024, representatives of Aadi shared with representatives of WuXi Biologics a draft license agreement between Aadi and WuXi Biologics in
respect of the ADC Programs as contemplated by the Term Sheet (the “License Agreement”).

On September 11, 2024, Aadi entered into a first
amendment to the mutual confidentiality agreement with WuXi Biologics and Hangzhou DAC which expanded the range of persons allowed access